Current News

PEI welcomes Phagenesis to Ireland

PEI has recently acquired the exclusive distribution rights for  PHAGENYX ™ the first dysphagia therapy clinically proven to improve swallow function by restoring neurological control. Dysphagia is a significant problem for many stroke patients.

Using Phagenyx™ when patients present with dysphagia will potentially:

  • Enable patients to swallow safely, improving nutritional status and prompting more independent feeding.
  • Reduce length of stay, enabling earlier discharge
  • Reduce risk of aspiration, helping to avoid pneumonia
  • Lead to a reduction in mortality risks associated with dysphagia after stroke

PHAGENYX™ consists of a base station and a catheter, which work together to deliver personalised treatment for every patient.